325 COMPARISON EFFICACY AND SAFETY BETWEEN ATEZOLIZUMAB PLUS BEVACIZUMAB AND LENVATINIB AS FIRST-LINE SYSTEMIC THERAPY FOR HEPATOCELLULAR CARCINOMA: A REAL-WORLD STUDY
Read More →
Maggio 2024
Risultati per: Carcinoma della prostata
Questo è quello che abbiamo trovato per te
Sa1032 A COMPREHENSIVE ANALYSIS OF HEPATOCELLULAR CARCINOMA MORTALITY IN THE UNITED STATES FOR 21 YEARS: A POPULATION-BASED TIME-TREND ANALYSIS
Read More →
Maggio 2024
Sa1029 DISPARITIES IN HEPATOCELLULAR CARCINOMA SURVIVAL AND MORTALITY: A LARGE NATIONAL CANCER REGISTRY ANALYSIS IN THE UNITED STATES
Read More →
Maggio 2024
Sa1557 EFFECTS OF METABOLIC RISK FACTORS ON THE RISK OF PROGRESSION TO CIRRHOSIS AND HEPATOCELLULAR CARCINOMA
Read More →
Maggio 2024
326 GENOME-WIDE CRISPR-CAS9 SCREENING IN PATIENT-DERIVED HEPATOCELLULAR CARCINOMA ORGANOID IDENTIFIES ESSENTIAL AND LENVATINIB RESISTANCE-ASSOCIATED GENES
Read More →
Maggio 2024
Su1105 SHIFTING AWAY FROM RACE-BASED GUIDELINES FOR SCREENING FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-CIRRHOTIC HBV
Read More →
Maggio 2024
Sa1530 PERCENTAGE OF BACTEROIDES SPEICIES IN MICROBIOME AFFECT THERAPEUTIC EFFICACY OF IMMUNE CHECKPOINT INHIBITORS FOR HEPATOCELLULAR CARCINOMA.
Read More →
Maggio 2024
1051 SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS ASSOCIATED WITH LOWER RISK OF HEPATOCELLULAR CARCINOMA AND HEPATIC DECOMPENSATION IN TYPE 2 DIABETES MELLITUS
Read More →
Maggio 2024
Mo1476 REGIONAL DIFFERENCE IN HEPATOCELLULAR CARCINOMA INCIDENCE TRENDS: A TWO-DECADE NATIONWIDE US ANALYSIS
Read More →
Maggio 2024
687 PERFORMANCE AND NUTRITIONAL STATUS ARE EACH INDEPENDENTLY ASSOCIATED WITH SURVIVAL IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING IMMUNOTHERAPY
Read More →
Maggio 2024
Mo1503 GLOBAL PREVALENCE, CLINICAL CHARACTERISTICS, SURVEILLANCE, TREATMENT ALLOCATION, AND OUTCOMES OF ALCOHOL-ASSOCIATED HEPATOCELLULAR CARCINOMA: SYSTEMATIC REVIEW AND METAANALYSIS
Read More →
Maggio 2024
Sa1648 CHECKING IS LACKING: SUBOPTIMAL SURVEILLANCE FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH SUSTAINED VIROLOGIC RESPONSE AFTER DIRECT-ACTING ANTIVIRAL THERAPY FOR HEPATITIS C
Read More →
Maggio 2024
Su1540 THE IMPACT OF GLP AGONISTS ON CIRRHOSIS, HEPATOCELLULAR CARCINOMA, AND MORTALITY IN PATIENTS WITH MASH: A FIVE-YEAR ANALYSIS
Read More →
Maggio 2024
Su1527 HIGHER INCIDENCE OF CIRRHOSIS AND HEPATOCELLULAR CARCINOMA IN LEAN VS. OVERWEIGHT/OBESE VETERANS WITH MASLD
Read More →
Maggio 2024
Tu1572 RACIAL DISPARITIES IN HEPATOCELLULAR CARCINOMA BASED ON TUMOR STAGE AT DIAGNOSIS: A NATIONWIDE POPULATION-BASED ANALYSIS USING THE UNITED STATES CANCER STATISTICS (USCS) DATABASE, 2001-2020
Read More →
Maggio 2024
Tu1581 DIDS INHIBITS THE CARCINOGENESIS AND GROWTH OF HEPATOCELLULAR CARCINOMA IN MICE
Read More →
Maggio 2024
